Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout

In this article

Neurocrine Biosciences

will acquire rare-disease drugmaker ⁠Soleno Therapeutics

for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused ​drugmaker’s expansion into ​metabolic disorders.

The deal ​gives Neurocrine access to Vykat XR, the first drug approved in the U.S. to treat hyperphagia associated with Prader-Willi syndrome, a rare genetic ⁠disorder, ‌bolstering its portfolio of rare-disease treatments.